Who Should Be Tested?

Both the National Comprehensive Cancer Network (NCCN®) and the American Society of Clinical Oncology (ASCO®) recommend determining HER-2 status for all patients with invasive breast cancer.

While it is recommended at initial diagnosis, HER-2 status can be determined at any time after initial diagnosis as well. There is discussion within the medical community that HER-2 status should be assessed with each occurrence or recurrence of invasive breast cancer.